Penny Flohr
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.
Journal: European urology oncology
Published: February 13, 2025
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.
Journal: Cancer cell
Published: April 12, 2024
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 16, 2024
Bench to Bedside Development of [18F]Fluoromethyl-(1,2-2H4)choline ([18F]D4-FCH).
Journal: Molecules (Basel, Switzerland)
Published: November 15, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Journal: Nature
Published: May 23, 2023
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Journal: Oncogene
Published: September 22, 2022
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Journal: Science (New York, N.Y.)
Published: October 07, 2021
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Journal: Cancer research
Published: October 04, 2021
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: August 07, 2019
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 03, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Journal: European urology
Published: November 19, 2018
Last Updated: 09/26/2026